​

LENZ Therapeutics Stock (NASDAQ:LENZ)

ForecastRevenueOwnershipFinancialsChartTranscripts
LENZ Therapeutics by TradingView

Previous Close

$9.38

52W Range

$8.25 - $50.40

50D Avg

$10.92

200D Avg

$25.12

Market Cap

$306.02M

Avg Vol (3M)

$949.17K

Beta

2.29

Div Yield

$7.21

LENZ Company Profile

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

6

IPO Date

Mar 22, 2024

Website

LENZ Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 25
License$17.50M
Product$1.59M

Fiscal year ends in Dec 25 | Currency in USD

LENZ Financial Summary

Dec 25Dec 24Dec 23
Revenue$19.09M--
Operating Income$-91.14M$-58.61M$-72.43M
Net Income$-82.13M$-49.77M$-69.97M
EBITDA$-91.14M$-49.71M$-72.41M
Basic EPS$-2.85$-2.34$-15.30
Diluted EPS$-2.85$-2.34$-15.30

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 25Mar 24, 26 | 8:30 AM
Q3 25Nov 05, 25 | 8:30 AM
Q1 25May 09, 25 | 4:30 PM

Peer Comparison

TickerCompany
NBTXNanobiotix S.A.
SPRYARS Pharmaceuticals, Inc.
ABUSArbutus Biopharma Corporation
RZLTRezolute, Inc.
GHRSGH Research PLC
TYRATyra Biosciences, Inc.
PRMEPrime Medicine, Inc.
MRVIMaravai LifeSciences Holdings, Inc.
SVRASavara Inc.
GERNGeron Corporation